Clinical Trial Update: Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update for tislelizumab plus bevacizumab and paclitaxel (pc) in untreated EGFR-mutant and high PD-L1 non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PC
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: UNKNOWN